AND017 vs Desidustat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

AND017

Developed by Kind Pharmaceuticals

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT05265325 · Phase 2 · completed

The study was randomized, triple-blind, and active-controlled, with 175 participants assigned to AND017 or standard erythropoiesis-stimulating therapy. However, the registry does not report whether the primary endpoints—adverse-event incidence and mean hemoglobin change at Week 6—were met, so the findings cannot be judged as demonstrating a positive effect.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07494409 (registry estimate)

No aligned efficacy figure on record for this race.

Desidustat · Oxemia

Marketed by Zydus Lifesciences and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT04012957 · Phase 3 · completed

The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Hemoglobin level (24 weeks): Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382) (met)

Result source: NCT04215120

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAND017Desidustat
Kidney composite outcome—Trial running · NCT07487727—Not posted · NCT04012957
UACR, % change—Trial running · NCT07487727—Not posted · NCT04012957
eGFR slope—Trial running · NCT07487727—Not posted · NCT04012957
Haemoglobin, change—Trial running · NCT074877271.9 vs 1.8avs darbepoetinNCT04012957
1 other result

Kidney composite outcome

AND017
—Trial running · NCT07487727
Desidustat
—Not posted · NCT04012957

UACR, % change

AND017
—Trial running · NCT07487727
Desidustat
—Not posted · NCT04012957

eGFR slope

AND017
—Trial running · NCT07487727
Desidustat
—Not posted · NCT04012957

Haemoglobin, change

AND017
—Trial running · NCT07487727
Desidustat
1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AND017: no structured comparison results are available for Chronic Kidney Disease.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Desidustat

Hemoglobin Change g/dL 1.95 vs 1.83 darbepoetin g/dL
absolute change · g/dL
NCT04012957 · Phase 3 · sponsor-reported, not registry data
show 1 more result
0.95 vs 0.8 epoetin alfa g/dL
NCT04215120 · Phase 3 · sponsor-reported, not registry data
Hemoglobin 77.78% vs 68.48% darbepoetin
responder rate · % of participants
NCT04012957 · Phase 3 · sponsor-reported, not registry data
show 1 more result
59.22% vs 48.37% epoetin alfa
NCT04215120 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AND017's landscape · Desidustat's landscape